Oncolytics Biotech Inc.

0.81
-0.07 (-7.95%)
At close: Jan 23, 2025, 3:59 PM
0.79
-1.94%
Pre-market Jan 24, 2025, 05:04 AM EST
undefined%
Bid 0.78
Market Cap 62.09M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.25
PE Ratio (ttm) -3.22
Forward PE n/a
Analyst Buy
Ask 0.82
Volume 1,712,161
Avg. Volume (20D) 1,126,020
Open 0.90
Previous Close 0.88
Day's Range 0.80 - 0.90
52-Week Range 0.71 - 1.53
Beta undefined

About ONCY

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with ...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2001
Employees 29
Stock Exchange NASDAQ
Ticker Symbol ONCY

Analyst Forecast

According to 2 analyst ratings, the average rating for ONCY stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 396.52% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 months ago
+18.22%
Oncolytics Biotech shares are trading higher after... Unlock content with Pro Subscription